- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01150214
DECAAF: Delayed-Enhancement MRI (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation (DECAAF)
DECAAF: DE-MRI Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation
This is a multi-center, observational, 1-year prospective cohort study (1 year follow-up, at 3, 6 and 12 month) with approximately 675 participants. We will conduct a thorough outcomes assessment utilizing data from Magnetic Resonance Imaging (MRI) scans, as well as pre-procedure and follow-up data. Scans will be blinded to location of participating site. MRI scans will be sequenced and analyzed as they arrive from the database.
Imaging Protocol: All patients will undergo a Delayed-Enhancement MRI (DE-MRI) within 30 days prior to the atrial fibrillation (AF) ablation procedure. The purpose of the initial MRI is to quantify the degree of atrial structural remodeling or fibrosis pre-ablation. Following ablation, DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
Clinical Follow-up: The institution where the ablation was performed will continue post-procedural care following standard of care procedures.
Atrial arrhythmia recurrences will be catalogued up to one year post-ablation and predictors of recurrences of AF will be determined by statistical analysis. The specific mechanism and electrophysiological characteristics of atrial arrhythmia recurrence will also be analyzed.
Our hypotheses are (1) DE-MRI will reproducibly stage the progression left atrium fibrosis in AF; (2) DE-MRI will reproducibly aid in quantifying and identifying the distribution of catheter ablation-related scarring in the left atrium; and (3) the stage of left atrium fibrosis pre-ablation and the amount and location of scarring will predict success of catheter ablation therapy for AF.
Studieoversikt
Detaljert beskrivelse
Atrial fibrillation (AF) is an electrophysiological condition characterized by a disorganized electrical activity in the atria of the heart. AF is associated with structural heart disease including hypertension, systolic and diastolic ventricular dysfunction and valvular heart disease. It represents a significant public health problem with the increasing longevity of the general population. A major determinant of the progression of AF is structural remodeling or fibrosis that occurs in the left atrium. A more extensively remodeled atrium represents the substrate needed for the arrhythmia to persist. Structural remodeling is also a major determinant for success of rhythm control strategies in AF. While catheter ablation has been reproducibly shown to be superior to anti-arrhythmic drug therapy for rhythm control in AF, the success of this procedure is significantly affected by the extent of structural remodeling present at the time of catheter ablation.
Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) has been demonstrated to be a very effective modality in identifying fibrotic and scarred cardiac tissue with excellent correlation with autopsy findings. This is related to the characteristics of Gadolinium, an extracellular contrast agent that is very effective in identifying regions of fibrotic non-viable myocardium. DE-MRI technology can be a very powerful, non-invasive method, of identifying the extent and the distribution of structural remodeling or fibrosis associated with AF.
Applying DE-MRI technology to the atrium causes significant technical challenges. The atrial wall is often a few millimeters thick which requires high spatial resolution to obtain adequate and useful images. In addition, image acquisition has to be gated to the diastolic phase of the atrial contraction cycle, which may be difficult to do when the patient is in AF. The ongoing research at the University of Utah has shown significant progress and very promising results overcoming the challenges mentioned. Specific image acquisition sequences have allowed for reproducible identification of high pixel intensity regions within the 2-dimensional images of the atrial wall. Three-dimensional reconstruction of the entire left atrium then provides a quantification of the overall volume occupied by these hyper-enhanced regions relative to the entire left atrial wall volume. Used prior to catheter ablation, DE-MRI can therefore identify regions of significant structural remodeling or fibrosis. The same technology has also been shown to be very useful in examining the amount and distribution of ablation related scarring.
Clinical patient characteristics will be collected for this study from clinic visits and chart reviews.
Imaging Protocol: All patients will undergo a DE-MRI within 30 days prior to the AF ablation procedure using a DE-MRI protocol. The purpose of the initial MRI is to quantify the degree of atrial structural remodeling or fibrosis pre-ablation. Following ablation, DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation (Figs. 4-5).
Clinical Follow-up: The institution where the ablation was performed will continue post-procedural care following standard of care procedures. Monitoring and definition of atrial arrhythmia AF recurrences will be guided by the HRS consensus document on ablation of atrial fibrillation.
Clinical and MRI data will be stored using the IRB-approved University of Utah database. De-identified clinical data and MRI images from participating institutions will also be submitted to the database, and will be processed at the University of Utah for pre- and post-ablation fibrosis and scar quantification. The ablation strategy utilized and procedural endpoint will be left to the discretion of the operators at the participating sites. This data will also be collected and included in the final analysis. MRI image processors at the University of Utah will be blinded to the ablation technique and mother institution using a unique de-identified study participant ID number.
Atrial arrhythmia recurrences will be catalogued up to one year post-ablation and predictors of recurrences determined by multivariate/survival analysis. The specific mechanism and electrophysiological characteristics of atrial arrhythmia recurrence will also be analyzed.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
South Australia
-
Norwood, South Australia, Australia, 5067
- Royal Adelaide Hospital
-
-
-
-
-
Ghent, Belgia, 9000
- Universitair Ziekenhuis Ghent
-
-
-
-
Florida
-
Tampa, Florida, Forente stater, 33606
- Florida Heart Rhythm Institute
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
-
Ohio
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania Hospital
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Sarah Cannon Research Institute (Centennial)
-
-
-
-
-
Bordeaux, Frankrike, 33604
- Hôpital Cardiologique du Haut-Lévêque/Bordeaux
-
-
-
-
-
Nieuwegein, Nederland, 3430
- St Antonius Ziekenhuis Hospital
-
-
-
-
Catalonia
-
Barcelona, Catalonia, Spania, 08036
- Hospital Clinic de Barcelona
-
-
-
-
-
Bad Nauheim, Tyskland, 61231
- Kerckhoff Klinik
-
Coburg, Tyskland, 96450
- Coburg Klinik
-
Cologne, Tyskland
- Institut für Diagnostische und Interventionelle Radiologie - koln
-
Hamburg, Tyskland, 20099
- Asklepios Klinik St. Georg
-
Leipzig, Tyskland, 04103
- Universitatsklinikum Leipzig
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patients who underwent an AF ablation as per recent Heart Rhythm Society (HRS) consensus document, as per the University of Utah AFIB Database (IRB_00020347)
- Patients who have had an MRI post-ablation.
- Age ≥18 years.
Exclusion Criteria:
- Contraindication for DE-MRI with a full dose of Gadolinium-based contrast agent.
- Previous left atrial ablation or surgical procedure
- Renal failure with CrCl <60 ml/min
- Women currently pregnant, breastfeeding, or of childbearing age not currently taking or not willing to use a reliable form of contraception
- Mental or physical inability to take part in the study
- Uncontrolled hypertension
- Morbid obesity (BMI > 35), or inability to be placed in MRI due to body mass.
- Patients who have not had a DE-MRI post-ablation.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
DE-MRI
All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
|
Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue.
DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Relationship between extent of pre-ablation fibrosis and recurrence post-ablation
Tidsramme: 1 year
|
The percentage of pre-ablation fibrosis in atrial fibrillation patients can significantly impact the incidence of recurrences post-ablation.
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Relationship between extent of Post-ablation scar and incidence of atrial fibrillation recurrences post-catheter ablation for AF
Tidsramme: Post-ablation scar
|
The extent of lesions created by ablation may have an impact on the incidence of recurrence of AF post-ablation
|
Post-ablation scar
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Nassir F Marrouce, MD, FHRS, CARMA Center, University of Utah
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Fish EN, Blauer JJ, Rao SN, DiBella EV, Segerson NM, Daccarett M, Windfelder J, McGann CJ, Parker D, MacLeod RS, Marrouche NF. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation. 2009 Apr 7;119(13):1758-67. doi: 10.1161/CIRCULATIONAHA.108.811877. Epub 2009 Mar 23.
- Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ; Heart Rhythm Society; European Heart Rhythm Association; European Cardiac Arrhythmia Society; American College of Cardiology; American Heart Association; Society of Thoracic Surgeons. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Endorsed and approved by the governing bodies of the American College of Cardiology, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, and the Heart Rhythm Society. Europace. 2007 Jun;9(6):335-79. doi: 10.1093/europace/eum120. No abstract available. Erratum In: Europace. 2009 Jan;11(1):132.
- McGann CJ, Kholmovski EG, Oakes RS, Blauer JJ, Daccarett M, Segerson N, Airey KJ, Akoum N, Fish E, Badger TJ, DiBella EV, Parker D, MacLeod RS, Marrouche NF. New magnetic resonance imaging-based method for defining the extent of left atrial wall injury after the ablation of atrial fibrillation. J Am Coll Cardiol. 2008 Oct 7;52(15):1263-71. doi: 10.1016/j.jacc.2008.05.062.
- Segerson NM, Daccarett M, Badger TJ, Shabaan A, Akoum N, Fish EN, Rao S, Burgon NS, Adjei-Poku Y, Kholmovski E, Vijayakumar S, DiBella EV, MacLeod RS, Marrouche NF. Magnetic resonance imaging-confirmed ablative debulking of the left atrial posterior wall and septum for treatment of persistent atrial fibrillation: rationale and initial experience. J Cardiovasc Electrophysiol. 2010 Feb;21(2):126-32. doi: 10.1111/j.1540-8167.2009.01611.x. Epub 2009 Oct 5.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB_00039522
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Atrieflimmer
-
Pusan National University HospitalHar ikke rekruttert ennåHjerteimplanterbar elektronisk enhet | Atrial High Rate EpisodeKorea, Republikken
-
Helios Klinikum PforzheimRekrutteringHøyre hjertesvikt | Trikuspidal regurgitasjon | Hjerteombygging, Ventrikulær | Hjerteombygging, atrialTyskland
-
Henry Ford Health SystemTilbaketrukket
-
The Second Affiliated Hospital of Chongqing Medical...UkjentAtrieflimmer | Hjerteombygging, atrial | Sacubitril/Valsartan
-
W.L.Gore & AssociatesFullført
-
Nobles Medical Technologies II IncPåmelding etter invitasjonForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater, Italia
-
HeartStitch.ComUkjentForamen Ovale, patent | Septal defekt, atrial | Septaldefekt, hjerteForente stater
-
China National Center for Cardiovascular DiseasesRekrutteringHjertesykdommer | Atrial septal dilatasjonKina
-
Assiut UniversityUkjent
-
Amsterdam UMC, location VUmcRekruttering
Kliniske studier på DE-MRI
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupUkjentBrystkreft | BIRADS 3 | BIRADS 4 | BIRADS 5Forente stater
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)Aktiv, ikke rekrutterendeHode- og nakkekreftForente stater
-
The Hospital for Sick ChildrenPåmelding etter invitasjon
-
Assiut UniversityUkjentMultippel sklerose
-
Fondation Ophtalmologique Adolphe de RothschildRekrutteringOptimaliserte MR-sekvenserFrankrike
-
Institut National de la Santé Et de la Recherche...Fullført
-
University of MilanFullført
-
Vanderbilt UniversityNational Institutes of Health (NIH)TilbaketrukketMR termisk avbildning av spedbarn som gjennomgår avkjøling for hypoksisk iskemisk encefalopati (HIE)Hypoksisk iskemisk encefalopatiForente stater
-
Stanford UniversityColumbia University; University of ManchesterRekruttering
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)RekrutteringSunn | Perifer nerveskade Øvre ekstremitetForente stater